Patents by Inventor James E. Crowe, Jr.

James E. Crowe, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090092609
    Abstract: The present invention is directed to particular human monoclonal antibodies and fragments thereof that find use in the detection, prevention and treatment of respiratory syncytial virus infections. In particular, these antibodies may neutralize RSV. Also disclosed are improved methods for producing monoclonal antibodies.
    Type: Application
    Filed: September 23, 2008
    Publication date: April 9, 2009
    Inventor: James E. Crowe, JR.
  • Patent number: 7488477
    Abstract: The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: April 30, 2003
    Date of Patent: February 10, 2009
    Assignee: Intracel Resources LLC
    Inventors: Glenn R. Pilkington, Page S. Gilmour, Robert M. Chanock, James E. Crowe, Jr., Brian R. Murphy
  • Patent number: 7364737
    Abstract: Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell line producing the monoclonal antibodies.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: April 29, 2008
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Carlos F. Barbas, III, Robert M. Chanock, Brian R. Murphy, James E. Crowe, Jr.
  • Patent number: 6685942
    Abstract: A method for providing passive immmunotherapy to respiratory syncytial virus (RSV) disease in a host is disclosed. The method includes administering to a host a human monoclonal antibody Fab fragment that neutralizes both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV), or a monoclonal antibody comprising the fragment.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: February 3, 2004
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Carlos F. Barbas, III, Robert M. Chanock, Brian R. Murphy, James E. Crowe, Jr.
  • Patent number: 6284254
    Abstract: The respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants and children throughout the world. RSV is a major cause of pneumonia and bronchiolitis in infants under one year of age, and is a major cause of fatal respiratory tract disease in these infants. The treatment and prevention of RSV infection has been problematic. However, the present invention addresses some of these concerns by providing attenuated RSV strains that are suitable for inclusion in immunizing compositions. Specifically, the present invention is directed toward the introduction of growth restriction mutations into incompletely attenuated host range-restricted cold-passaged respiratory syncytial virus (cpRSV) strains by further passage of the strains at increasingly reduced temperatures to produce derivative strains which are more satisfactorily attenuated.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: September 4, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Brian R. Murphy, Robert M. Chanock, James E. Crowe, Jr., Mark Connors, Kuo-Hom Lee Hsu, Alan R. Davis, Michael D. Lubeck, Bernard H. Selling
  • Patent number: 5922326
    Abstract: The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: July 13, 1999
    Assignee: The United States of America, as represented by the Department of Health & Human Services
    Inventors: Brian R. Murphy, Robert M. Chanock, James E. Crowe, Jr., Mark Connors
  • Patent number: 5882651
    Abstract: The present invention provides vaccine compositions of attenuated respiratory syncytial virus (RSV). More particularly, the attenuated virus may be a derivative of RSV which has been incompletely attenuated by cold-passage or introduction of mutations which produce virus having a temperature sensitive (ts) or cold adapted (ca) phenotype. The invention also provides methods for stimulating the immune system of an individual to induce protection against respiratory syncytial virus by administration of attenuated RSV. The invention also provides pure cultures of attenuated RS virus, wherein the virus has been more completely attenuated by the further derivatization of previously identified incompletely attenuated ts or cp mutants.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: March 16, 1999
    Assignees: United States of America, American Home Products Corporation
    Inventors: Brian R. Murphy, Robert M. Chanock, James E. Crowe, Jr., Mark Connors, Kuo-Hom Lee Hsu, Alan R. Davis, Michael D. Lubeck, Bernard H. Selling
  • Patent number: 5762905
    Abstract: Human monoclonal antibodies and fragments thereof which bind and neutralize respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell lines producing the monoclonal antibodies.
    Type: Grant
    Filed: December 10, 1993
    Date of Patent: June 9, 1998
    Assignee: The Scripps Research Institute
    Inventors: Dennis R. Burton, Carlos F. Barbas, III, Robert M. Chanock, Brian R. Murphy, James E. Crowe, Jr.